Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 5
2007 4
2008 5
2009 7
2010 7
2011 9
2012 10
2013 8
2014 9
2015 7
2016 8
2017 12
2018 6
2019 6
2020 11
2021 14
2022 16
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
Bastos-Oreiro M, Gutierrez A, Cabero A, López J, Villafuerte P, Jiménez-Ubieto A, de Oña R, De la Fuente A, Navarro B, Peñalver J, Martínez P, Alonso C, Infante M, Córdoba R, Perez-Montero B, Pérez de Oteyza J, González de Villambrosio S, Fernández-Caldas P, Del Campo R, García Belmonte D, Diaz-Gálvez J, Salar A, Sancho JM. Bastos-Oreiro M, et al. Among authors: salar a. Cancers (Basel). 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285. Cancers (Basel). 2024. PMID: 38610963 Free PMC article.
Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas.
Diez-Feijóo R, Andrade-Campos M, Gibert J, Sánchez-González B, Fernández-Ibarrondo L, Fernández-Rodríguez C, Garcia-Gisbert N, Camacho L, Lafuente M, Vázquez I, Colomo L, Salar A, Bellosillo B. Diez-Feijóo R, et al. Among authors: salar a. Cancers (Basel). 2024 Jan 11;16(2):321. doi: 10.3390/cancers16020321. Cancers (Basel). 2024. PMID: 38254810 Free PMC article.
Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience.
Gutierrez A, Alonso A, Garcia-Recio M, Perez S, Garcia-Maño L, Martinez-Serra J, Ros T, Garcia-Gasalla M, Ferrer J, Vögler O, Alemany R, Salar A, Sampol A, Bento L. Gutierrez A, et al. Among authors: salar a. Front Immunol. 2023 Nov 1;14:1267485. doi: 10.3389/fimmu.2023.1267485. eCollection 2023. Front Immunol. 2023. PMID: 38022668 Free PMC article.
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Muntañola A, Villalobos MT, González-Villambrosia S, Rodríguez-Salazar MJ, Jiménez-Ubieto A, Bastidas-Mora G, Córdoba R, Infante M, Vidal MJ, Díaz FJ, Baile M, Bastos-Oreiro M, Panizo C, Sancho JM, Navarro B, García T, Escoda L, Abrisqueta P, Terol MJ, de Campo R, Mozas P, López-Guillermo A, Salar A, Montalbán C; GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Muntañola A, et al. Among authors: salar a. Br J Haematol. 2023 Aug;202(4):776-784. doi: 10.1111/bjh.18912. Epub 2023 Jun 30. Br J Haematol. 2023. PMID: 37386877
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.
Canales MA, Buchholz TA, Bortolini JAP, Fogliatto LM, Ishikawa T, Izutsu K, Salar A, Sharman JP, Klingbiel D, Pokala S, Vorozheikina E, Trask P, Parreira J, Hübel K. Canales MA, et al. Among authors: salar a. Hemasphere. 2023 Mar 30;7(4):e860. doi: 10.1097/HS9.0000000000000860. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37008164 Free PMC article. No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M. Pirosa MC, et al. Among authors: salar a. Haematologica. 2023 Jun 1;108(6):1671-1675. doi: 10.3324/haematol.2022.281963. Haematologica. 2023. PMID: 36546422 Free PMC article. Clinical Trial. No abstract available.
Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A, Arguiñano-Pérez JM, Dávila J, de Villambrosia SG, Carpio C, Jiménez-Ubieto A, Salar A; GELTAMO (Grupo español de linfomas y trasplante de médula ósea). Muntañola A, et al. Among authors: salar a. Clin Transl Sci. 2023 Feb;16(2):305-312. doi: 10.1111/cts.13450. Epub 2022 Nov 24. Clin Transl Sci. 2023. PMID: 36385738 Free PMC article.
133 results